Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial

IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC). OBJECTIVE: To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) in patients with advanced N...

Descripción completa

Detalles Bibliográficos
Autores principales: Morizane, Chigusa, Machida, Nozomu, Honma, Yoshitaka, Okusaka, Takuji, Boku, Narikazu, Kato, Ken, Nomura, Shogo, Hiraoka, Nobuyoshi, Sekine, Shigeki, Taniguchi, Hirokazu, Okano, Naohiro, Yamaguchi, Kensei, Sato, Takuji, Ikeda, Masafumi, Mizuno, Nobumasa, Ozaka, Masato, Kataoka, Tomoko, Ueno, Makoto, Kitagawa, Yuko, Terashima, Masanori, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389440/
https://www.ncbi.nlm.nih.gov/pubmed/35980649
http://dx.doi.org/10.1001/jamaoncol.2022.3395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389440/
https://www.ncbi.nlm.nih.gov/pubmed/35980649
http://dx.doi.org/10.1001/jamaoncol.2022.3395

Ejemplares similares